JSC Grindeks plans to increase its turnover to 70 million lats this year. That will be achieved by strengthening positions in the current markets, entering new markets and increasing range of generic products.
Competition in the pharmaceutical market is tough, Mildronate® analogues are introduced in many markets, however, taking into account the advantages of the original product Mildronate® – unique quality control methods, starting from the substance development and ending with the final dosage products, recently successfully finished clinical trial on the influence of the brand product Mildronate® on the treatment of angina and others – Grindeks is several steps ahead of the competitors.
During last years Grindeks intensively introduces new products, and has launched such demanded products as medications in curing schizophrenia Rispaxol®, sorbent Sorbex®, anti cancer medications – Axastrol®, Bicalutamide and others.
JSC Grindeks main markets are the Baltic states, Russia and other CIS countries. However JSC Grindeks purposefully operates in Eastern Europe, the Balkans and in the region of Scandinavia and has started exporting of final dosage medications to Rumania, Slovakia, Albania, Kosovo, Sweden and Finland.
Grindeks Chairman of the Board Jānis Romanovskis: „High business goals will be achieved, thanks to know-how of Grindeks about markets, flexible approach to changes, the new shareholder – Russian company “Pharmstandard” and professionalism of employees.”
Grindeks is the leading pharmaceutical company in the Baltic States. Its main fields of action are: research, development, manufacturing and sale of original products, generics and active pharmaceutical ingredients. Grindeks specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups.
Group consists of four subsidiary companies in Latvia, Estonia and Russia, as well representatives and representative offices in fourteen countries. Products of the company are exported to more than 40 countries and its export comprises more than 96% of the total turnover. The main markets are: the Baltic States, Russia and other CIS countries, Japan, USA. JSC Grindeks shares are listed in the Official List of “Nasdaq OMX Riga”.
Head of the Communications Department
Phones: (+371) 67083370, (+371) 29256012
Fax: (+371) 67083505